(00:33)
 Could you please tell the audience a little bit about yourself and your background before we get to?

(01:07)
 So just as an overview, this new MAG test, can you kind of give us a general idea of the assay, the methodology, and how this could be used clinically?

(01:59)
 Can you maybe expound upon the role of the M protein, how it relates to the MAG antibody and also that unique testing methodology that we use?

(03:15)
 Can you describe how those will present to our listeners and then when it would be appropriate to order this specific test?

(03:56)
 And is the antibody test important or is it pretty clear this DADs phenotype is separate from maybe other types of neuropathies?

(05:25)

I think the other thing that's exciting is just about how the antibody test can help increase confidence for physicians, right?

(05:50)

Can you talk to me about how our test is maybe different than how other existing MAG antibody tests that already exist on the market?

(07:20)

I've also heard you talk about the reference ranges, where, depending on where the cutoffs are, it can increase, I think specificity, is that right, Dr. Mills?

(08:30)

I've also heard to test for SGPG that oftentimes accompanies MAG, but I noticed that we won't be using that complimentary tests. Can you help our listeners understand why?

(09:42)

Can you just elaborate again on how this test can impact patient care and maybe shorten that journey?

(10:56)

So a test result that's positive for MAG, the physician can have a lot of confidence that that's really the underlying etiology?

(11:33)

Are we seeing it more often that patients are going to test positive for the MAG antibody, and that should lead them to getting this M protein tested for using our MASS fixation technology?

(13:14)

Now, if a patient is found to be positive for the M protein as well, uh, how does that change the treatment or prognosis for those DADs phenotype patients?

(14:09)

Dr. Mills, if you could summarize for our physicians this to key takeaway for physicians or patient impact related to this test, what would it be?